
At Debiopharm, every step we take is guided by one purpose: improving the lives of people affected by cancer and infectious diseases. As a privately-owned Swiss biopharmaceutical company, we’re driven by science, but above all, by the people behind every treatment — the patients and their families.
Through our unique “development only” model, we bring forward promising therapies and transform them into treatments that can reach those who need them most, faster.
Are you ready to be at the forefront of the model-informed drug development (MIDD)? Debiopharm International SA is seeking a highly motivated Research Fellow (Intern) to help build an AI-enhanced Quantitative Systems Pharmacology (QSP) platform. This project offers a unique opportunity to integrate preclinical, clinical data and real-world data with mathematical models and AI to accelerate the development of our Antibody-Drug Conjugate (ADC) pipeline. You will work directly on assets, bridging the gap between systems biology and data-driven decision-making.
Location: Lausanne, Switzerland
Department: Clinical Pharmacology & Pharmacometrics
Project: 12-months internship
The primary mission of this fellowship is to develop and standardize a custom QSP platform for the Debiopharm ADC pipeline. By utilizing AI and advanced modeling techniques, you will contribute to a "Digital Twin" environment to simulate virtual trials, optimize dosing regimens, and establish "Go/No-Go" criteria. This role is central to a specific project strategy, aiming to shorten development timelines and enhance our proprietary MIDD capabilities.
Requirements
Benefits
If your application is selected, you’ll be invited to interviews with Talent Acquisition and the Hiring Manager via Teams, followed by a panel interview and reference checks. Communication is handled via Workable—check your spam folder for emails from *@outbound.workable.com.
Please contact our HR Department prior to submitting any profiles. We cannot accept unsolicited applications from agencies or recruiters.

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe.
Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections.
Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®
If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!